nach oben

Reactions Weekly

Erschienen in:

01.05.2022 | Case report

Dabrafenib/pembrolizumab/trametinib

Fatigue, and pure red cell aplasia following off-label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

The age of the patient 3 was stated as 55 years in the case presentation, and 54 years in the table 1. The age of patient has been considered as 55 years based on case presentation.

McCrary HC, et al. Mutation based approaches to the treatment of anaplastic thyroid cancer. Clinical Endocrinology 96: 734-742, No. 5, May 2022. Available from: URL: https://onlinelibrary.wiley.com/doi/10.1111/cen.14679

Titel: Dabrafenib/pembrolizumab/trametinib
Fatigue, and pure red cell aplasia following off-label use: case report
Publikationsdatum: 01.05.2022
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-15924-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Diazoxide

Camrelizumab/rivoceranib

Paraffin

Cotrimoxazole/lisinopril interaction

Multiple drugs

Dapagliflozin